Development and manufacture of recombinant proteins and peptides, in partnership with big pharmas. Includes licensing of technology derived from the host-defense protein BPI, monoclonal antibodies to treat chemotherapy-induced thrombocytopenia, and to target cancer. Based in Berkeley, California.
Xoma